WallStreetZenWallStreetZen

NASDAQ: VERA
Vera Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VERA

Based on 6 analysts offering 12 month price targets for Vera Therapeutics Inc

Min Forecast
$26.00-8.64%
Avg Forecast
$61.17+114.92%
Max Forecast
$100.00+251.37%

Should I buy or sell VERA stock?

Based on 6 analysts offering ratings for Vera Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 50%
Buy
2 analysts 33.33%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although VERA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates VERA as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their VERA stock forecasts and price targets.

VERA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-16
lockedlocked$00.00+00.00%2025-08-07
lockedlocked$00.00+00.00%2025-06-02
lockedlocked$00.00+00.00%2025-05-12
lockedlocked$00.00+00.00%2025-05-07
Cantor Fitzgerald
Top 15%
86
Strong BuyMaintains$100.00+251.37%2025-05-07

1 of 1

Forecast return on equity

Is VERA forecast to generate an efficient return?

Company
7.97%
Industry
237.05%
Market
142.96%
VERA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VERA forecast to generate an efficient return on assets?

Company
6.45%
Industry
106.32%
VERA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VERA earnings per share forecast

What is VERA's earnings per share in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
-$4.17
Avg 2 year Forecast
-$4.74
Avg 3 year Forecast
-$3.43

VERA revenue forecast

What is VERA's revenue in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$37.4M
Avg 3 year Forecast
$206.5M

VERA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VERA$28.46$61.17+114.92%Strong Buy
BHVN$17.20$45.46+164.27%Strong Buy
NUVB$5.22$7.80+49.43%Buy
CLDX$26.73$41.67+55.88%Buy
VCEL$35.06$55.33+57.82%Strong Buy
View Top Biotech Stocks

Vera Therapeutics Stock Forecast FAQ

Is Vera Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: VERA) stock is to Strong Buy VERA stock.

Out of 6 analysts, 3 (50%) are recommending VERA as a Strong Buy, 2 (33.33%) are recommending VERA as a Buy, 1 (16.67%) are recommending VERA as a Hold, 0 (0%) are recommending VERA as a Sell, and 0 (0%) are recommending VERA as a Strong Sell.

If you're new to stock investing, here's how to buy Vera Therapeutics stock.

What is VERA's earnings growth forecast for 2025-2027?

(NASDAQ: VERA) Vera Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41%.

Vera Therapeutics's earnings in 2025 is -$218,282,000.On average, 15 Wall Street analysts forecast VERA's earnings for 2025 to be -$266,100,006, with the lowest VERA earnings forecast at -$304,604,824, and the highest VERA earnings forecast at -$162,175,933. On average, 14 Wall Street analysts forecast VERA's earnings for 2026 to be -$302,607,143, with the lowest VERA earnings forecast at -$401,552,971, and the highest VERA earnings forecast at -$207,746,030.

In 2027, VERA is forecast to generate -$219,023,671 in earnings, with the lowest earnings forecast at -$325,870,869 and the highest earnings forecast at -$120,626,727.

What is VERA's revenue growth forecast for 2025-2027?

(NASDAQ: VERA) Vera Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.

Vera Therapeutics's revenue in 2025 is $0.On average, 13 Wall Street analysts forecast VERA's revenue for 2025 to be $0, with the lowest VERA revenue forecast at $0, and the highest VERA revenue forecast at $0. On average, 14 Wall Street analysts forecast VERA's revenue for 2026 to be $2,384,388,301, with the lowest VERA revenue forecast at $160,835,636, and the highest VERA revenue forecast at $4,258,314,929.

In 2027, VERA is forecast to generate $13,177,033,876 in revenue, with the lowest revenue forecast at $4,660,850,784 and the highest revenue forecast at $29,459,089,054.

What is VERA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: VERA) forecast ROA is 6.45%, which is lower than the forecast US Biotechnology industry average of 106.32%.

What is VERA's Price Target?

According to 6 Wall Street analysts that have issued a 1 year VERA price target, the average VERA price target is $61.17, with the highest VERA stock price forecast at $100.00 and the lowest VERA stock price forecast at $26.00.

On average, Wall Street analysts predict that Vera Therapeutics's share price could reach $61.17 by Oct 16, 2026. The average Vera Therapeutics stock price prediction forecasts a potential upside of 114.92% from the current VERA share price of $28.46.

What is VERA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: VERA) Vera Therapeutics's current Earnings Per Share (EPS) is -$3.58. On average, analysts forecast that VERA's EPS will be -$4.17 for 2025, with the lowest EPS forecast at -$4.77, and the highest EPS forecast at -$2.54. On average, analysts forecast that VERA's EPS will be -$4.74 for 2026, with the lowest EPS forecast at -$6.29, and the highest EPS forecast at -$3.26. In 2027, VERA's EPS is forecast to hit -$3.43 (min: -$5.11, max: -$1.89).

What is VERA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: VERA) forecast ROE is 7.97%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.